Zevra Therapeutics Provides FDA Update On The PDUFA Action Date For Arimoclomol As A Treatment For Niemann-Pick Disease Type C

CELEBRATION, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has extended the review period...

https://www.drugs.com/nda/arimoclomol_240304.html

Source: Drugs.com - New Drug Applications - March 4, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications | Niemann-Pick Disease | Rare Diseases